International Trade Bulletin - Volume 1, Issue 9
Client Alert | 1 min read | 07.10.06
Inside this issue:
- EUROPE IN THE SPOTLIGHT
- EU Anti-Dumping: The Latest Series of Anti-Dumping Measures Proposed by the EU Clearly Show the Fingerprints of a More Liberalized Policy
- Market Access: The European Commission Formally Kicked Off Its Strategic Review of EU-China Trade Relations on 7th July With a High-Profile Conference in Brussels
- CHINA IN THE SPOTLIGHT
- U.S. EXPORT CONTROLS: US-India Agreement May Give U.S.-India Tech Transfers A Yellow Light
- U.S. SANCTIONS: State Department Shifts Policies Toward Venezuela and Libya on Trade Sanctions
- TECHNOLOGY: New U.S. Legislation Could Impose Significant Penalties Against U.S. Companies that Provide Information to Internet-Restricting Countries Such as China
- CUSTOMS: Potential Backlog in U.S. Validations Causes Concern for C-TPAT Members
- TRANSPORTATION: Supporters of U.S. Department of Transport's (“DOT”) Foreign Control Proposal Seek Changes to Expand Foreign Control While Opponents Argue the Rule Already Permits Too Much Foreign Control
- ANTI-BOYCOTT OAC Issues Proposed Anti-Boycott Penalty Guidelines
Contacts
Insights
Client Alert | 4 min read | 09.16.26
CMS Offers Guidance as Scrutiny Rises Over ABA Therapy in Medicaid
Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy. In 2025, Medicaid spent about $10 billion on ABA and related therapy services for children with ASD — a dramatic increase from the $2 billion spent in 2021.
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
